Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
This grant supports the continued operation of national biobanks for collecting, storing, and distributing cancer clinical trial biospecimens to advance translational cancer research.
Funder: National Institutes of Health
Due Dates: July 14, 2026 (Estimated)
Funding Amounts: Estimated total program funding: $19,100,000; ~6 awards expected.
Summary: Supports the continuation of NCI biospecimen banks for clinical trials, enabling high-quality biospecimen collection and translational cancer research.
Key Information: Limited competition; only current NCTN/EET biobank awardees eligible.
Description
This forecasted opportunity from the National Cancer Institute (NCI), part of the NIH, will support the continued operation of two major biospecimen banking resources: the National Clinical Trials Network (NCTN) Biospecimen Banks and the Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank). These resources are critical for collecting, processing, storing, and distributing clinically annotated human biospecimens from NCI-funded clinical trials. The aim is to ensure ongoing access to high-quality biospecimens for translational cancer research, biomarker development, and scientific discovery.
The NCTN Biobanks primarily support large, multi-site clinical trials in adult and childhood cancers, facilitating research on disease mechanisms, therapeutic response, and clinical outcomes. The EET Biobank focuses on early-phase and experimental clinical trials, supporting studies on investigational new drugs (INDs), biomarker assay development, drug action, and resistance mechanisms.
This is a limited competition opportunity, restricted to institutions/entities that currently operate NCTN or EET biobanks funded under previous related RFAs.
